Quarterly report · Q1
4361.TEDINET S100QJKH
Period2022-12-01 → 2023-02-28
Filed2023-04-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.1bn | 2022-12-01 → 2023-02-28 | Cons. | Net sales |
| Revenue | ¥8.4bn | 2021-12-01 → 2022-11-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.9bn | 2021-12-01 → 2022-02-28 | Cons. | Net sales |
| Operating income | ¥47m | 2022-12-01 → 2023-02-28 | Cons. | Operating income |
| Operating income | ¥114m | 2021-12-01 → 2022-02-28 | Cons. | Operating income |
| Ordinary income | ¥46m | 2022-12-01 → 2023-02-28 | Cons. | Ordinary income |
| Ordinary income | ¥303m | 2021-12-01 → 2022-11-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥118m | 2021-12-01 → 2022-02-28 | Cons. | Ordinary income |
| Profit before tax | ¥46m | 2022-12-01 → 2023-02-28 | Cons. | Income before income taxes |
| Profit before tax | ¥118m | 2021-12-01 → 2022-02-28 | Cons. | Income before income taxes |
| Net income (owners) | ¥41m | 2022-12-01 → 2023-02-28 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥219m | 2021-12-01 → 2022-11-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥95m | 2021-12-01 → 2022-02-28 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥41m | 2022-12-01 → 2023-02-28 | Cons. | Profit loss |
| Net income | ¥95m | 2021-12-01 → 2022-02-28 | Cons. | Profit loss |
| Total assets | ¥8.2bn | at 2023-02-28 | Cons. | Assets |
| Total assets | ¥8.3bn | at 2022-11-30 | Cons. | Assets |
| Total assets | ¥7.8bn | at 2022-02-28 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.8bn | at 2023-02-28 | Cons. | Liabilities |
| Total liabilities | ¥5.9bn | at 2022-11-30 | Cons. | Liabilities |
| Net assets / equity | ¥2.4bn | at 2023-02-28 | Cons. | Net assets |
| Net assets / equity | ¥2.4bn | at 2022-11-30 | Cons. | Net assets |
| Net assets / equity | ¥2.3bn | at 2022-02-28 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥864m | at 2023-02-28 | Cons. | Cash and deposits |
| Cash and deposits | ¥911m | at 2022-11-30 | Cons. | Cash and deposits |
| EPS (basic) | ¥33.77 | 2022-12-01 → 2023-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥179.75 | 2021-12-01 → 2022-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥78.24 | 2021-12-01 → 2022-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 29.1% | at 2023-02-28 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 29.0% | at 2022-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 29.4% | at 2022-02-28 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 18
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q1r_E01006-000Pharmaceutical Productsreportable segment | revenue | 2022-12-01 → 2023-02-28 | ¥2.0bn |
| jpcrp040300-q1r_E01006-000Pharmaceutical Productsreportable segment | revenue external | 2022-12-01 → 2023-02-28 | ¥2.0bn |
| jpcrp040300-q1r_E01006-000Pharmaceutical Productsreportable segment | segment profit | 2022-12-01 → 2023-02-28 | ¥39m |
| jpcrp040300-q1r_E01006-000Real Estate Leasingreportable segment | revenue | 2022-12-01 → 2023-02-28 | ¥10m |
| jpcrp040300-q1r_E01006-000Real Estate Leasingreportable segment | revenue external | 2022-12-01 → 2023-02-28 | ¥10m |
| jpcrp040300-q1r_E01006-000Real Estate Leasingreportable segment | segment profit | 2022-12-01 → 2023-02-28 | ¥8m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-12-01 → 2023-02-28 | ¥2.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-12-01 → 2023-02-28 | ¥2.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-12-01 → 2023-02-28 | ¥47m |
| jpcrp040300-q1r_E01006-000Pharmaceutical Productsreportable segment | revenue | 2021-12-01 → 2022-02-28 | ¥1.9bn |
| jpcrp040300-q1r_E01006-000Pharmaceutical Productsreportable segment | revenue external | 2021-12-01 → 2022-02-28 | ¥1.9bn |
| jpcrp040300-q1r_E01006-000Pharmaceutical Productsreportable segment | segment profit | 2021-12-01 → 2022-02-28 | ¥106m |
| jpcrp040300-q1r_E01006-000Real Estate Leasingreportable segment | revenue | 2021-12-01 → 2022-02-28 | ¥9m |
| jpcrp040300-q1r_E01006-000Real Estate Leasingreportable segment | revenue external | 2021-12-01 → 2022-02-28 | ¥9m |
| jpcrp040300-q1r_E01006-000Real Estate Leasingreportable segment | segment profit | 2021-12-01 → 2022-02-28 | ¥8m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-12-01 → 2022-02-28 | ¥1.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-12-01 → 2022-02-28 | ¥1.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-12-01 → 2022-02-28 | ¥114m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 337
| Item | Context | Value | Unit |
|---|---|---|---|
| Comprehensive income attributable to owners of the parent | Prior1YTDDuration | 92527000 | JPY |
| Comprehensive income attributable to owners of the parent | CurrentYTDDuration | 46680000 | JPY |
| Comprehensive income attributable to non controlling interests | Prior1YTDDuration | － | JPY |
| Comprehensive income attributable to non controlling interests | CurrentYTDDuration | － | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E01006-000PharmaceuticalProductsReportableSegmentsMember | 1933940000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E01006-000RealEstateLeasingReportableSegmentMember | 9497000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 1943437000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 1943437000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E01006-000PharmaceuticalProductsReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E01006-000RealEstateLeasingReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E01006-000PharmaceuticalProductsReportableSegmentsMember | 1933940000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E01006-000RealEstateLeasingReportableSegmentMember | 9497000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 1943437000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1YTDDuration | 1943437000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E01006-000PharmaceuticalProductsReportableSegmentsMember | 106408000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E01006-000RealEstateLeasingReportableSegmentMember | 7595000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 114004000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Operating income | Prior1YTDDuration | 114004000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E01006-000PharmaceuticalProductsReportableSegmentsMember | 2042442000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E01006-000RealEstateLeasingReportableSegmentMember | 9547000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 2051990000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 2051990000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E01006-000PharmaceuticalProductsReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E01006-000RealEstateLeasingReportableSegmentMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q1r_E01006-000PharmaceuticalProductsReportableSegmentsMember | 2042442000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q1r_E01006-000RealEstateLeasingReportableSegmentMember | 9547000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 2051990000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Net sales | CurrentYTDDuration | 2051990000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q1r_E01006-000PharmaceuticalProductsReportableSegmentsMember | 38859000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q1r_E01006-000RealEstateLeasingReportableSegmentMember | 7645000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 46504000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Operating income | CurrentYTDDuration | 46504000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2023-04-10 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第122期第１四半期(自 2022年12月１日 至 2023年２月28日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)川口化学工業株式会社 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |